Symbiotec Pharmalab IPO
GMP, Subscription, Price, Dates & Financial Details
Pharmaceutical & Drugs
Symbiotec Pharmalab Ltd., incorporated in 2002, is a pharmaceutical and biotechnology company engaged in the research, development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products. The Company caters to customers in both domestic and…
Open Date
Mon, 24 Aug 2026
Close Date
Thu, 27 Aug 2026
Price Band
₹ 938 – 988
Lot Size
15
Issue Size
₹ 1,757.00 Cr
Minimum Investment
₹ 14,820 (15 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Symbiotec Pharmalab IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹1,757.00 Crore, comprising a fresh issue of 15.21 Lakh equity shares aggregating to ₹150.00 Crore and an offer for sale (OFS) of 1.63 Crore equity shares aggregating to ₹1,607.00 Crore by the existing shareholders.
The Symbiotec Pharmalab IPO remained open for subscription from August 24, 2026, to August 27, 2026. The basis of allotment was finalized on August 28, 2026, and the company's shares were listed on the NSE and BSE on September 01, 2026.
The company had fixed the price band at ₹938 to ₹988 per share, with a lot size of 15 shares. Retail investors were required to make a minimum investment of ₹14,820 (based on the upper price band) to apply for one lot.
The IPO also included a reservation of 33,408 equity shares for eligible employees, who received a discount of ₹90 per share.
MUFG Intime India Pvt Ltd served as the registrar to the issue. Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd, JM Financial Limited, and Nomura Financial Advisory And Securities (India) Pvt Ltd acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Symbiotec Pharmalab Limited is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Symbiotec Pharmalab IPO Timeline (Tentative)
- IPO Open Date
- Mon, 24 Aug 26
- IPO Close Date
- Thu, 27 Aug 26
- Basis of Allotment
- Fri, 28 Aug 26
- Initiation of Refunds
- Mon, 31 Aug 26
- Credit of Shares to Demat
- Mon, 31 Aug 26
- Listing Date
- Tue, 01 Sep 26 — BSE & NSE
Open Date
24 August 2026
Close Date
27 August 2026
Basis Of Allotment
28 August 2026
Listing Date
01 September 2026
IPO Subscription
Check Live Subscription →The Symbiotec Pharmalab IPO has received bids for 93,52,49,700 shares against 1,59,29,833 shares offered, resulting in an overall subscription of 71.26x. the NII category is subscribed 73.63x, Retail Investors 12.96x, Employees 15.41x, and QIBs 172.03x. Within the NII category, BNII is subscribed 82.92x, while SNII is subscribed 55.07x.
QIB
172.03x
NII
73.63x
BNII
82.92x
SNII
55.07x
RII
12.96x
EMP
15.41x
Total
71.26x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 62,13,562 shares, representing 34.93% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 35,50,608 shares (19.96%), while Non-Institutional Investors (NIIs) receive 26,62,955 shares (14.97%).
| Category | Shares Offered | Shares Offered |
|---|---|---|
| Anchor Investors | 5,325,909 | 29.94% |
| Qualified Institutions | 3,550,608 | 19.96% |
| Non-Institutional | 2,662,955 | 14.97% |
| BNII | 1,775,303 | 9.98% |
| SNII | 887,652 | 4.99% |
| Retail Investors | 6,213,562 | 34.93% |
| Employees | 33,408 | 0.19% |
| Total | 17,786,442 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1780.79 | 1579.65 | 1294.79 |
| Revenue | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.9 | 96.79 | 100.06 |
| Net Worth | 1158.64 | 821.15 | 720.68 |
| Reserve & Surplus | 1145.95 | 810.03 | 709.54 |
| Total Borrowings | 387.91 | 540.92 | 247.21 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Symbiotec Pharmalab Limited KPI Information
| Particular | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| ROE % | 11.19 | 12.66 | 14.98 |
| ROCE % | 11.56 | 11.8 | 14.03 |
| RoNW % | 9.48 | 11.79 | 13.9 |
| Pat Margin % | 12.6 | 12.8 | 13.83 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Symbiotec Pharmalab Ltd | 2 | 0 | 19.1 | 19 | 9.48 | 184.69 |
| Concord Biotech Ltd | 1 | 61.07 | 24.78 | 24.78 | 14 | 0 |
| Divi's Laboratories Ltd | 2 | 87.8 | 96.75 | 96.75 | 16.5 | 631 |
| Cohance Lifesciences Ltd | 1 | 95.02 | 4.69 | 4.68 | 7 | 0 |
| Laurus Labs Limited | 2 | 109.36 | 16.47 | 16.45 | 16.8 | 0 |
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab Ltd., incorporated in 2002, is a pharmaceutical and biotechnology company engaged in the research, development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products. The Company caters to customers in both domestic and international markets, with a presence across regulated and emerging pharmaceutical markets.
With more than three decades of industry experience, Symbiotec Pharmalab has evolved from a laboratory-scale manufacturer of steroidal hormone APIs in 1995 into an industrial-scale, backward-integrated manufacturing platform. The Company's integrated capabilities span research and development, manufacturing and quality control, enabling it to support the production of specialized pharmaceutical and nutritional ingredients at scale.
Regulatory and Quality Standards
Symbiotec Pharmalab operates in accordance with stringent international quality and regulatory requirements. The Company has obtained approvals and certifications from various global regulatory authorities and organizations, including the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP) and the Ministry of Food and Drug Safety (MFDS), Korea, among other regulatory bodies. These approvals support the Company's ability to supply products to highly regulated international markets.
Manufacturing Capabilities
As of June 30, 2025, Symbiotec Pharmalab operated two industrial-scale API manufacturing facilities. The facilities had a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and a fermentation capacity of 300 kilolitres.
The Company's backward-integrated manufacturing capabilities enable greater control over its production processes and raw material requirements, while supporting consistency in quality, operational efficiency and supply reliability.
Research, Quality and Sustainability
Symbiotec Pharmalab follows a research-driven manufacturing approach, with a focus on product development, process improvement and quality compliance. Its manufacturing operations are designed to meet global pharmaceutical standards while emphasizing efficient and sustainable production practices.
The Company serves a diverse range of end-use industries, including pharmaceuticals, nutraceuticals and wellness, by supplying high-quality APIs, nutritional ingredients and specialty products that are developed and manufactured in accordance with applicable global quality standards.
Overall, Symbiotec Pharmalab has built an integrated pharmaceutical manufacturing platform supported by long-standing industry experience, regulatory approvals, manufacturing scale, backward integration and research capabilities, positioning it to serve customers across both regulated and emerging global markets.
Symbiotec Pharmalab IPO Promoters
Anil Satwani
Kashish Satwani
Sushil Satwani
Satwani Holdings LLP
Promoters Holding
Holding Pre Issue
36.39%
Holding Post Issue
26.55%
Symbiotec Pharmalab IPO Objective
Symbiotec Pharmalab Limited Address / Contact Details
Symbiotec Pharmalab Ltd.
385/2, Pigdamber, Rau,Mhow,
Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: https://www.symbiotec.com/
IPO Snapshot
Symbiotec Pharmalab IPO Lot Size
The Symbiotec Pharmalab IPO has a lot size of 15 shares. Retail investors require a minimum investment of ₹14,820 by applying for 1 lot (15 shares). The maximum application allowed for the retail category is 13 lots (195 shares), requiring an investment of ₹1,92,660.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 15 | 14,820.00 |
| Retail (Max) | 13 | 195 | 192,660.00 |
| S-HNI (Min) | 14 | 210 | 207,480.00 |
| S-HNI (Max) | 67 | 1,005 | 992,940.00 |
| B-HNI (Min) | 68 | 1,020 | 1,007,760.00 |
Issue Reservation
- Anchor Investors — 29.94%
- QIB — 19.96%
- NII — 14.97%
- RII — 34.93%
- EMP — 0.19%
Book Running Lead Managers
- Avendus Capital Pvt.Ltd.
- Motilal Oswal Investment Advisors Ltd
- JM Financial Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
More About Symbiotec Pharmalab IPO
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Symbiotec Pharmalab IPO?
Symbiotec Pharmalab IPO is a Book-building IPO with a total issue size of ₹1757 crore. The Symbiotec Pharmalab IPO price band is ₹938 to 988 per share. The Symbiotec Pharmalab IPO subscription opens on Mon, Aug 24, 2026, and closes on Thu, Aug 27, 2026. The Symbiotec Pharmalab IPO will be listed on the BSE,NSE. MUFG Intime India Pvt Ltd is the registrar for the Symbiotec Pharmalab IPO.
When will the Symbiotec Pharmalab IPO open for subscription?
The Symbiotec Pharmalab IPO opens on Mon, Aug 24, 2026 and closes on Thu, Aug 27, 2026
What is Symbiotec Pharmalab IPO Price Band?
Symbiotec Pharmalab IPO Price Band is ₹938 to 988 per share.
What is Symbiotec Pharmalab IPO Lot Size?
Symbiotec Pharmalab IPO lot size is 15 shares, Retail investors need a minimum investment of ₹14820 based on the upper price band
What is the minimum investment for Symbiotec Pharmalab IPO?
The minimum investment for Symbiotec Pharmalab IPO is ₹14820, based on one lot of 15 shares at the upper price band of ₹988 per share.
How to apply for Symbiotec Pharmalab IPO?
Investors can apply for the Symbiotec Pharmalab IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Thu, Aug 27, 2026. The application amount remains blocked until the Symbiotec Pharmalab IPO allotment is finalized.
What is Symbiotec Pharmalab IPO Issue Size?
Symbiotec Pharmalab IPO issue size is ₹1757 crores.
What is the Symbiotec Pharmalab IPO Allotment Date?
Symbiotec Pharmalab IPO allotment date is Fri, Aug 28, 2026.
Who is the Symbiotec Pharmalab IPO Registrar?
The registrar for Symbiotec Pharmalab IPO is MUFG Intime India Pvt Ltd. Investors can go to MUFG Intime India Pvt Ltd website to check Symbiotec Pharmalab IPO allotment status, refund processing, and other IPO-related information.
What is the Symbiotec Pharmalab IPO GMP?
The Symbiotec Pharmalab IPO GMP (Grey Market Premium) is ₹270 as of Thu, Aug 27, 2026. Based on the upper price band of ₹988 per share, the estimated Symbiotec Pharmalab IPO listing price is ₹1258, indicating a potential listing gain of approximately 27.33% over the issue price.
Who is the Symbiotec Pharmalab IPO Lead Manager?
The book-running lead managers (BRLMs) for the Symbiotec Pharmalab IPO are Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd, JM Financial Limited and Nomura Financial Advisory And Securities (India) Pvt Ltd. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Symbiotec Pharmalab IPO Red Herring Prospectus (RHP).